Related Experiment Videos

Evaluation of the endogenous glucocorticoid hypothesis of denervation atrophy

Insights

This study found that RU38486, a glucocorticoid antagonist, did not alter muscle changes after denervation in rats. Therefore, enhanced sensitivity to glucocorticoids does not cause denervation atrophy.

Area of Science:

  • Muscle physiology
  • Endocrinology
  • Neuroscience

Background:

  • Skeletal muscle denervation leads to atrophy.
  • Glucocorticoids are implicated in muscle wasting.
  • RU38486 is a selective glucocorticoid receptor antagonist.

Purpose of the Study:

  • To investigate the role of glucocorticoids in denervation-induced skeletal muscle atrophy.
  • To determine if blocking glucocorticoid receptors with RU38486 affects muscle wasting parameters.

Main Methods:

  • Oral administration of RU38486 to rats.
  • Skeletal muscle denervation was performed.
  • Measurements included muscle weight, non-collagen protein content, and enzyme activities (choline acetyltransferase, glucose-6-phosphate dehydrogenase, glutamine synthetase).

Main Results:

  • RU38486 did not affect the decrease in muscle weight or protein content.
  • RU38486 did not alter choline acetyltransferase activity.
  • RU38486 did not affect the increase in glucose-6-phosphate dehydrogenase and glutamine synthetase activities.

Conclusions:

  • The findings do not support the hypothesis that denervation atrophy is caused by increased muscle sensitivity to endogenous glucocorticoids.
  • Glucocorticoid antagonism does not prevent or modify the atrophic changes in skeletal muscle following denervation.

Related Concept Videos